These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 3295122)

  • 41. The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis.
    Filipović SR; Drulović J; Stojsavljević N; Lević Z
    J Neurol Sci; 1997 Nov; 152(2):147-53. PubMed ID: 9415535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relapses in multiple sclerosis: effects of high-dose steroids on cortical excitability.
    Ayache SS; Créange A; Farhat WH; Zouari HG; Mylius V; Ahdab R; Abdellaoui M; Lefaucheur JP
    Eur J Neurol; 2014 Apr; 21(4):630-6. PubMed ID: 24471453
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.
    Filippini G; Brusaferri F; Sibley WA; Citterio A; Ciucci G; Midgard R; Candelise L
    Cochrane Database Syst Rev; 2000; 2000(4):CD001331. PubMed ID: 11034713
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis.
    Hansen TM; Kryger P; Elling H; Haar D; Kreutzfeldt M; Ingeman-Nielsen MW; Olsson AT; Pedersen C; Rahbek A; Tvede N
    BMJ; 1990 Aug; 301(6746):268-70. PubMed ID: 2202458
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis.
    Sellebjerg F; Jensen CV; Larsson HB; Frederiksen JL
    Mult Scler; 2003 Feb; 9(1):102-7. PubMed ID: 12617276
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré Syndrome Steroid Trial Group.
    Lancet; 1993 Mar; 341(8845):586-90. PubMed ID: 8094828
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prospective evaluation of the effectiveness of high doses of methylprednisolone in multiple sclerosis].
    Wajgt A; Szczechowski L; Marczewska E; Grechuta M; Strzyzewska L; Gadomska B; Szyrocka-Szwed K
    Neurol Neurochir Pol; 1988; 22(3):188-94. PubMed ID: 3065667
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early immunosuppressive effect of parenteral methylprednisolone in the treatment of multiple sclerosis.
    Durelli L; Baggio GF; Bergamasco B; Barile C; Cocito D; Delsedime M; Perla F; Riccio A; Bergamini L
    Acta Neurol (Napoli); 1985; 7(3-4):338-44. PubMed ID: 3904340
    [No Abstract]   [Full Text] [Related]  

  • 50. [Prospective assessment of combined treatment with high doses of intravenous methylprednisolone and long term administration of Isoprinosine in multiple sclerosis patients].
    Maciejek Z; Niezgodzińska-Maciejek A
    Neurol Neurochir Pol; 1993; 27(3):321-9. PubMed ID: 7694166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial.
    Barnes MP; Bates D; Cartlidge NE; French JM; Shaw DA
    J Neurol Neurosurg Psychiatry; 1987 Nov; 50(11):1402-6. PubMed ID: 3320274
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheumatoid disease.
    Williams IA; Baylis EM; Shipley ME
    Lancet; 1982 Jul; 2(8292):237-40. PubMed ID: 6124671
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
    van de Wyngaert FA; Beguin C; D'Hooghe MB; Dooms G; Lissoir F; Carton H; Sindic CJ
    Acta Neurol Belg; 2001 Dec; 101(4):210-6. PubMed ID: 11851027
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of oral prednisolone tapering following intravenous methyl prednisolone in patients with multiple sclerosis relapses: A randomized, double-blind, placebo-controlled trial.
    Bazi A; Baghbanian SM; Ghazaeian M; Saeedi M; Hendoiee N
    Mult Scler Relat Disord; 2021 Jan; 47():102640. PubMed ID: 33310419
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment.
    Edwards JC; Snaith ML; Isenberg DA
    Ann Rheum Dis; 1987 Oct; 46(10):773-6. PubMed ID: 3318723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.
    Sorensen PS; Haas J; Sellebjerg F; Olsson T; Ravnborg M;
    Neurology; 2004 Dec; 63(11):2028-33. PubMed ID: 15596745
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-dose intravenous corticosteroids in the treatment of multiple sclerosis.
    Ohno R; Hamaguchi K; Sowa K; Tanaka H; Watanabe Y
    Jpn J Med; 1987 May; 26(2):212-6. PubMed ID: 3626160
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.
    Ozakbas S; Cinar BP; Kosehasanoğullari G; Kahraman T; Oz D; Kursun BB
    Clin Neurol Neurosurg; 2017 Sep; 160():69-72. PubMed ID: 28689102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative evaluations of neuroperformance and clinical outcome assessments in chronic progressive multiple sclerosis: I. Reliability, validity and sensitivity to disease progression. Multiple Sclerosis Study Group.
    Syndulko K; Ke D; Ellison GW; Baumhefner RW; Myers LW; Tourtellotte WW
    Mult Scler; 1996 Oct; 2(3):142-56. PubMed ID: 9345379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.